BioClinica to Highlight New Trident IWR Release at DIA Meeting.

- Exhibit Will Showcase eClinical Portfolio Interoperability -

NEWTOWN, Pa. -- BioClinica([R]), Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced a new release of Trident IWR, the latest addition to its best-in-class suite of eClinical applications. BioClinica will highlight Trident and other new product offerings at booth #1417, providing demonstrations of BioClinica's Integrated Clinical Trial Solutions, including:

* Trident IWR Randomization to Express EDC

* Express CRF Status to OnPoint CTMS and Clinical Payment Manager

* Trident + Optimizer 360 Degree Clinical Supplies Forecasting and Management

* Unified Reporting

* Customer Portals

* Microsoft Office Interoperability

* Ad Hoc Reporting

BioClinica will also participate in a clinical solutions showcase for the Microsoft platform, where they will demonstrate BioClinica's open, standards-based architecture within the Microsoft Connected Life Sciences Framework guidance.

"Fewer drugs make it to market each year, yet many pharmaceutical companies continue to use the same development processes and procedures within an antiquated architecture," said Michael Naimoli, Worldwide Managing Director, Life Sciences, Microsoft. "Microsoft and several partners, including BioClinica, worked together to develop a standard approach to information architecture across the industry that could enable companies to unlock valuable data, such as information that could lead to new therapies, and share that data among partners, customers and even regulatory agencies."

To see the benefits of this solution, please visit Microsoft at booth #1111 and BioClinica at booth #1417. The DIA 2011 Annual Meeting is being held in Chicago from June 20 - 23, with exhibits opened June 20 - 22.

Trident IWR provides clinical operations personnel an intuitive way to directly set up, monitor, and maintain randomization and supplies for their clinical trials. Trident's powerful parameter-driven study set-up eliminates programming for each new clinical trial and it configures both web and voice at the same time. This leads to greater efficiencies in starting new studies in a less costly manner and in a fraction of the time than other alternatives. This new release enhances Trident's capabilities for features such as managing temperature sensitive supplies and advanced supply pooling.

"Trident is truly changing the IWR landscape," said Mark Weinstein, CEO of BioClinica. "Clinical studies using Trident are typically developed and deployed within weeks. The combination of set-up speed and support for configuring even complex designs allows sponsors to make mid-study or last minute changes without affecting study timelines. This solution is literally changing what people can do with IWR/ IVR."

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.